<DOC>
	<DOCNO>NCT02646774</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety intravenous micafungin treatment proven probable fungal infection cause Aspergillus sp . ( Fungemia , respiratory mycosis , gastrointestinal mycosis ) adult patient China .</brief_summary>
	<brief_title>Post Marketing Study Evaluate Efficacy Safety Micafungin Treatment Invasive Aspergillosis</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Patients diagnose proven probable infection cause aspergillus ( include fungemia , respiratory mycosis gastrointestinal mycosis ) reference definition EORTC/MSG Females childbearing potential pregnant study reliable method contraception maintain whole study . Patients capable understand purpose risk study , willing able participate study write date informed consent participate study obtain . Patient receive echinocandins drug within 1 month prior enrollment . Patient enrol clinical study within last month . AST/ALT &gt; 5 time upper limit normal ( ULN ) total bilirubin &gt; 2.5 time ULN BUN/Ccr &gt; 3 time ULN HIV positive patient Patient history hypersensitivity , serious reaction component product echinocandins . Patient life expectancy &lt; 1 month Subject unlikely comply visit schedule protocol opinion investigator history noncompliance . Pregnant woman , nurse mother , lactate woman , woman childbearing potential unwilling use reliable contraception duration study 6 week follow completion study . Patient previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Aspergillosis</keyword>
	<keyword>Antifungal</keyword>
	<keyword>Micafungin</keyword>
</DOC>